Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Gabapentin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | USP2 | O75604 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gabapentin SCHEMBL6672099 | 1.00 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL3238880 | 0.98 | CYP1A2 (0.92) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL3117115 | 0.98 | CYP1A2 (0.92) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL7047893 | 0.98 | CYP1A2 (0.92) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL8343 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL466183 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL6544499 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL179836 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL4030100 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL19031792 | 0.96 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693410-B | Preparation method of gabapentin with controllable particle size | 浙江竹子制药有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-116693410-A | Preparation method of gabapentin with controllable particle size | 浙江竹子制药有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116675615-A | Synthesis method of high-purity gabapentin | 浙江竹子制药有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-104496833-B | A kind of synthesis technique of gabapentin | 太仓运通生物化工有限公司 | 2016-08-24 | — | — | CN | claimed |
| CN-104496833-A | Gabapentin synthesis technology | TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD | 2015-04-08 | — | — | CN | claimed |
| CN-104447372-A | Preparation method of gabapentin | TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD | 2015-03-25 | — | — | CN | claimed |
| CN-104402744-A | Preparation method for gabapentin | TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD | 2015-03-11 | — | — | CN | claimed |
| US-7442834-B2 | Process suitable for industrial scale production of gabapentin | ZHEJIANG CHIRAL MEDICINE CHEMICALS CO., LTD. (CN) | 2008-10-28 | — | — | US | claimed |
| CN-100398513-C | Production of gabapendin | ZHEJIANG SHOUXIN MEDICAL CHEMI (CN) | 2008-07-02 | — | — | CN | claimed |
| US-20070287861-A1 | A Process Suitable for Industrial Scale Production of Gabapentin | ZHEJIANG CHIRAL MEDICINE CHEMICALS CO., LTD. | 2007-12-13 | — | — | US | claimed |
| CN-1896050-A | Production of gabapendin | SHOUXIN MEDICAL CHEMICAL PRODU (CN) | 2007-01-17 | — | — | CN | claimed |
| CN-1568305-A | Novel anhydrous crystalline form of gabapentin | WARNER LAMBERT CO (US) | 2005-01-19 | — | — | CN | claimed |
| EP-1463712-A1 | NEW ANHYDROUS CRYSTALLINE FORMS OF GABAPENTIN | Warner-Lambert Company LLC (US) | 2004-10-06 | — | — | EP | claimed |
| US-6800782-B2 | DEHYDRATING GABAPENTIN MONOHYDRATE TO FORM CRYSTALLINE GABAPENTIN DEHYDRATE FORM A, ALLOWING DEHYDRATE A TO STAND AT AMBIENT TEMPERATURES TO FORM CRYSTALLINE GABAPENTIN DEHYDRATE FORM B | WARNER-LAMBERT CO. | 2004-10-05 | — | — | US | claimed |
| US-20030092933-A1 | Anhydrous crystalline forms of gabapentin | CHEN LINNA R (US) | 2003-05-15 | — | — | US | claimed |
| WO-2003031391-A1 | NEW ANHYDROUS CRYSTALLINE FORMS OF GABAPENTIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-17 | — | — | WO | claimed |
| EP-0340677-B1 | Gabapentin monohydrate and a process for producing the same | WARNER LAMBERT CO (US) | 1994-02-02 | — | — | EP | claimed |
| US-4960931-A | Anticonvulsants | WARNER-LAMBERT COMPANY (US) | 1990-10-02 | — | — | US | claimed |
| EP-0340677-A2 | Gabapentin monohydrate and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1989-11-08 | — | — | EP | claimed |
| JP-2011546-A | — | — | None | — | — | JP | disclosed |
| JP-2011546-A | — | — | None | — | — | JP | disclosed |
| CN-116693410-B | Preparation method of gabapentin with controllable particle size | 浙江竹子制药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-116693410-B | Preparation method of gabapentin with controllable particle size | 浙江竹子制药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-11931334-B2 | Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal | PLEOPHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-116693410-A | Preparation method of gabapentin with controllable particle size | 浙江竹子制药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116693410-A | Preparation method of gabapentin with controllable particle size | 浙江竹子制药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116675615-A | Synthesis method of high-purity gabapentin | 浙江竹子制药有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4114379-A1 | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND MITIGATING CANNABINOID WITHDRAWAL | Pleopharma, L.L.C. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11197846-B2 | Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal | PLEOPHARMA L.L.C. (US) | 2021-12-14 | — | — | US | disclosed |
| WO-2021178700-A1 | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND MITIGATING CANNABINOID WITHDRAWAL | Pleopharma, L.L.C. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210275492-A1 | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND MITIGATING CANNABINOID WITHDRAWAL | PLEOPHARMA, INC. | 2021-09-09 | — | — | US | disclosed |
| CN-105612145-B | Process for preparing gabapentin | F.I.S.-菲博利佳意大利合成面料股份公司 | 2017-11-24 | — | — | CN | disclosed |
| EP-3060544-B1 | PROCESS FOR PREPARING GABAPENTIN | F I S - FABBRICA ITALIANA SINTETICI S P A (IT) | 2017-08-30 | — | — | EP | disclosed |
| US-9481635-B2 | Process for preparing gabapentin | ZACH SYSTEM S.P.A. (IT) | 2016-11-01 | — | — | US | disclosed |
| EP-3060544-A1 | PROCESS FOR PREPARING GABAPENTIN | ZaCh System S.p.A. (IT) | 2016-08-31 | — | — | EP | disclosed |
| CN-104496833-B | A kind of synthesis technique of gabapentin | 太仓运通生物化工有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-104496833-B | A kind of synthesis technique of gabapentin | 太仓运通生物化工有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-20160237025-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
| WO-2015059150-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2015-04-30 | — | — | WO | disclosed |
| CN-104496833-A | Gabapentin synthesis technology | TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD | 2015-04-08 | — | — | CN | disclosed |
| CN-104496833-A | Gabapentin synthesis technology | TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD | 2015-04-08 | — | — | CN | disclosed |
| CN-104447372-A | Preparation method of gabapentin | TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD | 2015-03-25 | — | — | CN | disclosed |
| CN-104447372-A | Preparation method of gabapentin | TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD | 2015-03-25 | — | — | CN | disclosed |
| CN-104402744-A | Preparation method for gabapentin | TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD | 2015-03-11 | — | — | CN | disclosed |
| US-8431739-B2 | Process for the preparation of gabapentin | Divi's Laboratories, Ltd. (IN) | 2013-04-30 | — | — | US | disclosed |
| US-20110306787-A1 | PROCESS FOR THE PREPARATION OF GABAPENTIN | DIVI'S LABORATORIES LIMITED (IN) | 2011-12-15 | — | — | US | disclosed |
| US-20100280118-A1 | Methods for treating substance dependence | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2183211-A1 | METHOD FOR PREPARING POLYMORPH FORM II OF GABAPENTIN | Medichem, S.A. (ES) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010023694-A2 | CRYSTALLINE FORMS OF GABAPENTIN AND PROCESS THEREOF | HIKAL LTD (IN) | 2010-03-04 | — | — | WO | disclosed |
| EP-1603863-B1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | HIKAL LTD (IN) | 2010-01-13 | — | — | EP | disclosed |
| US-7635717-B2 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED (IN) | 2009-12-22 | — | — | US | disclosed |
| WO-2009055059-A1 | METHODS FOR TREATING SUBSTANCE DEPENDENCE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090043126-A1 | Process and Methods for the Preparation of Gabapentin and Its Intermediates | MEDICHEM S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| EP-2020993-A2 | SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTIN | Combino Pharm, S.L. (ES) | 2009-02-11 | — | — | EP | disclosed |
| WO-2009015685-A1 | METHOD FOR PREPARING POLYMORPH FORM II OF GABAPENTIN | MEDICHEM, S.A. (ES) | 2009-02-05 | — | — | WO | disclosed |
| EP-2007710-A1 | PREPARATION OF GABAPENTIN BY LIQUID-LIQUID EXTRACTION | Teva Pharmaceutical Industries Ltd. (IL) | 2008-12-31 | — | — | EP | disclosed |
| US-20080318932-A1 | Sodium Channel Blocker Compositions and the Use Thereof | PURDUE PHARMA L.P. (US) | 2008-12-25 | — | — | US | disclosed |
| US-7442834-B2 | Process suitable for industrial scale production of gabapentin | ZHEJIANG CHIRAL MEDICINE CHEMICALS CO., LTD. (CN) | 2008-10-28 | — | — | US | disclosed |
| US-7439387-B2 | Process for the preparation of Gabapentin form-II | MATRIX LABORATORIES LTD. (IN) | 2008-10-21 | — | — | US | disclosed |
| WO-2008106217-A1 | PREPARATION OF GABAPENTIN BY LIQUID-LIQUID EXTRACTION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207945-A1 | Preparation of gabapentin by liquid-liquid extraction | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
| CN-100398513-C | Production of gabapendin | ZHEJIANG SHOUXIN MEDICAL CHEMI (CN) | 2008-07-02 | — | — | CN | disclosed |
| CN-100398513-C | Production of gabapendin | ZHEJIANG SHOUXIN MEDICAL CHEMI (CN) | 2008-07-02 | — | — | CN | disclosed |
| US-7393872-B2 | Sodium channel blocker compositions and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-07-01 | — | — | US | disclosed |
| EP-1619181-B1 | Processes for the preparation of gabapentin | SANDOZ AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20070287861-A1 | A Process Suitable for Industrial Scale Production of Gabapentin | ZHEJIANG CHIRAL MEDICINE CHEMICALS CO., LTD. | 2007-12-13 | — | — | US | disclosed |
| WO-2007128495-A2 | SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTIN | COMBINO PHARM, S.L. (ES) | 2007-11-15 | — | — | WO | disclosed |
| EP-1853551-A1 | PROCESS AND METHODS FOR THE PREPARATION OF GABAPENTIN AND ITS INTERMEDIATES | Medichem, S.A. (ES) | 2007-11-14 | — | — | EP | disclosed |
| CN-100346779-C | Liquid pharmaceutical composition | WARNER LAMBERT CO (US) | 2007-11-07 | — | — | CN | disclosed |
| US-7256216-B2 | Liquid pharmaceutical compositions | WARNER-LAMBERT COMPANY LLC | 2007-08-14 | — | — | US | disclosed |
| EP-1765767-A1 | PROCESS FOR THE PREPARATION OF GABAPENTIN | Sandoz AG (CH) | 2007-03-28 | — | — | EP | disclosed |
| US-20070043236-A1 | Process for preparation of gabapentin | CHANDIRAN THAKASHINA M | 2007-02-22 | — | — | US | disclosed |
| CN-1896050-A | Production of gabapendin | SHOUXIN MEDICAL CHEMICAL PRODU (CN) | 2007-01-17 | — | — | CN | disclosed |
| CN-1896050-A | Production of gabapendin | SHOUXIN MEDICAL CHEMICAL PRODU (CN) | 2007-01-17 | — | — | CN | disclosed |
| US-20060287392-A1 | GABAPENTIN COMPOSITIONS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060235079-A1 | Process for the preparation of gabapentin form-II | MYLAN LABORATORIES LIMITED (IN) | 2006-10-19 | — | — | US | disclosed |
| CN-1832735-A | New dosage regimen in case of concurrent intake of gabapentin with food and an increased oral bioavailability therewith | RANBAXY LAB LTD (IN) | 2006-09-13 | — | — | CN | disclosed |
| WO-2006090208-A1 | PROCESS AND METHODS FOR THE PREPARATION OF GABAPENTIN AND ITS INTERMEDIATES | MEDICHEM S.A. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-7098362-B2 | Processes for the preparation of gabapentin | SANDOZ AG (CH) | 2006-08-29 | — | — | US | disclosed |
| EP-1636163-A4 | PROCESS FOR THE PREPARATION OF GABAPENTIN | SHASUN CHEMICALS AND DRUGS LTD (IN) | 2006-08-09 | — | — | EP | disclosed |
| EP-1395242-B1 | LIQUID PHARMACEUTICAL COMPOSITION | WARNER LAMBERT CO (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED | 2006-07-06 | — | — | US | disclosed |
| US-7056951-B2 | Stable solid dosage forms of amino acids and processes for producing same | MUTUAL PHARMACEUTICAL CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1636163-A1 | PROCESS FOR THE PREPARATION OF GABAPENTIN | Shasun Chemicals and Drugs Limited (IN) | 2006-03-22 | — | — | EP | disclosed |
| US-20060020034-A1 | Processes for the preparation of Gabapentin | SANDOZ AG (CH) | 2006-01-26 | — | — | US | disclosed |
| EP-1619181-A1 | Processes for the preparation of gabapentin | Sandoz AG (CH) | 2006-01-25 | — | — | EP | disclosed |
| EP-1615875-A2 | PROCESS FOR THE PREPARATION OF GABAPENTIN FORM-II | Matrix Laboratories Limited (IN) | 2006-01-18 | — | — | EP | disclosed |
| WO-2006002972-A1 | PROCESS FOR THE PREPARATION OF GABAPENTIN | SANDOZ AG (CH) | 2006-01-12 | — | — | WO | disclosed |
| EP-1603863-A1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | Hikal Ltd. (IN) | 2005-12-14 | — | — | EP | disclosed |
| EP-1169060-B1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005009432-A1 | NEW DOSAGE REGIMEN IN CASE OF CONCURRENT INTAKE OF GABAPENTIN WITH FOOD AND AN INCREASED ORAL BIOAVAILABILITY THEREWITH | RANBAXY LABORATORIES LIMITED (IN) | 2005-02-03 | — | — | WO | disclosed |
| CN-1568305-A | Novel anhydrous crystalline form of gabapentin | WARNER LAMBERT CO (US) | 2005-01-19 | — | — | CN | disclosed |
| CN-1568305-A | Novel anhydrous crystalline form of gabapentin | WARNER LAMBERT CO (US) | 2005-01-19 | — | — | CN | disclosed |
| WO-2004110981-A1 | A PROCESS FOR THE PREPARATION OF GABAPENTIN FORM-II | MATRIX LABORATORIES LTD (IN) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110342-A2 | NOVEL POLYMORPH OF GABAPENTIN AND ITS CONVERSION TO GABAPENTIN FORM-II | MATRIX LABORATORIES LTD (IN) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004106281-A1 | CRYSTALLINE GABAPENTIN | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004101489-A1 | PROCESS FOR THE PREPARATION OF GABAPENTIN | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004093780-A2 | PROCESS FOR THE PREPARATION OF GABAPENTIN FORM-II | MATRIX LABORATORIES LTD (IN) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214893-A1 | tartaric acid, ethanedisulfonic acid, or maleic acid salts of gabapentin; improved aqueous solubility, and dose response properties; for treating brain disorders | TRANSFORM PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2004091278-A2 | GABAPENTIN COMPOSITIONS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-1463712-A1 | NEW ANHYDROUS CRYSTALLINE FORMS OF GABAPENTIN | Warner-Lambert Company LLC (US) | 2004-10-06 | — | — | EP | disclosed |
| EP-1463712-A1 | NEW ANHYDROUS CRYSTALLINE FORMS OF GABAPENTIN | Warner-Lambert Company LLC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-6800782-B2 | DEHYDRATING GABAPENTIN MONOHYDRATE TO FORM CRYSTALLINE GABAPENTIN DEHYDRATE FORM A, ALLOWING DEHYDRATE A TO STAND AT AMBIENT TEMPERATURES TO FORM CRYSTALLINE GABAPENTIN DEHYDRATE FORM B | WARNER-LAMBERT CO. | 2004-10-05 | — | — | US | disclosed |
| US-6800782-B2 | DEHYDRATING GABAPENTIN MONOHYDRATE TO FORM CRYSTALLINE GABAPENTIN DEHYDRATE FORM A, ALLOWING DEHYDRATE A TO STAND AT AMBIENT TEMPERATURES TO FORM CRYSTALLINE GABAPENTIN DEHYDRATE FORM B | WARNER-LAMBERT CO. | 2004-10-05 | — | — | US | disclosed |
| CN-1509165-A | Liquid pharmaceutical composition | ����-�����ع�˾ | 2004-06-30 | — | — | CN | disclosed |
| WO-2004046085-A1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | HIKAL LTD. (IN) | 2004-06-03 | — | — | WO | disclosed |
| US-20040072904-A1 | Liquid pharmaceutical compositions | VIATRIS SPECIALTY LLC. | 2004-04-15 | — | — | US | disclosed |
| US-20040054005-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| EP-1395242-A1 | LIQUID PHARMACEUTICAL COMPOSITION | Warner-Lambert Company LLC (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1083164-B1 | NON-HYDRATED GABAPENTIN POLYMORPH, PRODUCTION PROCESS AND UTILIZATION FOR PRODUCING PHARMACEUTICAL GRADE GABAPENTIN | MEDICHEM SA (ES) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003070683-A1 | PREPARATION OF NEW MINERAL ACID ADDITION SALTS OF GABAPENTIN | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2003-08-28 | — | — | WO | disclosed |
| EP-1322335-A2 | STABLE SOLID DOSAGE FORMS OF AMINO ACIDS AND PROCESSES FOR PRODUCING SAME | Sigmapharm, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030092933-A1 | Anhydrous crystalline forms of gabapentin | CHEN LINNA R (US) | 2003-05-15 | — | — | US | disclosed |
| US-20030092933-A1 | Anhydrous crystalline forms of gabapentin | CHEN LINNA R (US) | 2003-05-15 | — | — | US | disclosed |
| WO-2003031391-A1 | NEW ANHYDROUS CRYSTALLINE FORMS OF GABAPENTIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003031391-A1 | NEW ANHYDROUS CRYSTALLINE FORMS OF GABAPENTIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-0950044-A4 | PREPARATION OF GABAPENTIN | TEVA PHARMA (IL) | 2003-03-26 | — | — | EP | disclosed |
| US-6538148-B2 | Catalytic hydrogenation | WARNER-LAMBERT COMPANY | 2003-03-25 | — | — | US | disclosed |
| US-20020198261-A1 | Liquid pharmaceutical compositions | KULKARNI NEEMA M (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2002094220-A1 | LIQUID PHARMACEUTICAL COMPOSITION | WARNER-LAMBERT COMPANY LLC (US) | 2002-11-28 | — | — | WO | disclosed |
| US-6372792-B1 | Method for treating anxiety, anxiety disorders and insomnia | CHOUINARD GUY (CA) | 2002-04-16 | — | — | US | disclosed |
| WO-2002026263-A2 | STABLE SOLID DOSAGE FORMS OF AMINO ACIDS AND PROCESSES FOR PRODUCING SAME | SIGMAPHARM, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA LTD. | 2002-03-28 | — | — | US | disclosed |
| WO-2000061188-A9 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-02-14 | — | — | WO | disclosed |
| US-20020010371-A1 | Process for preparing a cyclic amino acid anticonvulsant compound | DEERING CARL FRANCIS (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1169060-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-09 | — | — | EP | disclosed |
| US-6294690-B1 | REACTING BENZONITRILE WITH ALKALI METAL IN AMMONIA OR AMINE IN SOLVENT TO FORM ANIONIC INTERMEDIATE, ALKYLATING WITH HALOACETIC ACID, HYDROGENATING RING, HYDROGENATING NITRILE TO AMINE TO PRODUCE GABAPENTIN | WARNER-LAMBERT COMPANY | 2001-09-25 | — | — | US | disclosed |
| US-6255526-B1 | REACTING SOLUTION OF GABAPENTIN HYDROCHLORIDE WITH ADDITIONAL AMINE IN A FIRST SOLVENT TO PRODUCE POLYMORPHIC PRECIPITATE FORM, THEN RECOVERING CONVERTED FORM FROM METHANOL SLURRY AND/OR CRYSTALLIZATION; TREATMENT OF CEREBRAL DISEASES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-07-03 | — | — | US | disclosed |
| EP-1095010-A1 | PROCESS FOR THE PREPARATION OF GABAPENTIN | ZAMBON GROUP S.p.A. (IT) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000061188-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-19 | — | — | WO | disclosed |
| US-6054482-A | Lactam-free amino acids | GODECKE AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| WO-2000001660-A1 | PROCESS FOR THE PREPARATION OF GABAPENTIN | ZAMBON GROUP S.P.A. (IT) | 2000-01-13 | — | — | WO | disclosed |
| EP-0950044-A1 | PREPARATION OF GABAPENTIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999018063-A2 | PROCESS FOR PREPARING A CYCLIC AMINO ACID ANTICONVULSANT COMPOUND | WARNER-LAMBERT COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998028255-A1 | PREPARATION OF GABAPENTIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1998-07-02 | — | — | WO | disclosed |
| US-5693845-A | Cyanocycloalkylacetic acid and ester intermediates for preparing cyclic amino acid anticonvulsant compounds | WARNER-LAMBERT COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0414262-B1 | Process for the preparation of cyclic amino anticonvulsant compounds | WARNER LAMBERT CO (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5362883-A | Process for cyclic amino acid anticonvulsant compounds | WARNER-LAMBERT COMPANY (US) | 1994-11-08 | — | — | US | disclosed |
| US-5319135-A | Process for cyclic amino acid anticonvulsant compounds | WARNER-LAMBERT COMPANY (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0340677-B1 | Gabapentin monohydrate and a process for producing the same | WARNER LAMBERT CO (US) | 1994-02-02 | — | — | EP | disclosed |
| EP-0340677-B1 | Gabapentin monohydrate and a process for producing the same | WARNER LAMBERT CO (US) | 1994-02-02 | — | — | EP | disclosed |
| US-5132451-A | Process for cyclic amino acid anticonvulsant compounds | WARNER-LAMBERT COMPANY (US) | 1992-07-21 | — | — | US | disclosed |
| US-5091567-A | Reacting cyclohexanone with phosphonoacetic acid ester, condensing with nitromethane, reducing, hydrolyzing | GODECKE AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| US-5068413-A | Process for the preparation of cyclic amino acids and intermediates useful in the process | GODECKE AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0414262-A2 | Process for the preparation of cyclic amino anticonvulsant compounds | WARNER-LAMBERT COMPANY (US) | 1991-02-27 | — | — | EP | disclosed |
| EP-0340677-A3 | GABAPENTIN MONOHYDRATE AND A PROCESS FOR PRODUCING THE SAME | — | 1990-12-27 | — | — | EP | disclosed |
| US-4960931-A | Anticonvulsants | WARNER-LAMBERT COMPANY (US) | 1990-10-02 | — | — | US | disclosed |
| JP-H0211546-A | GABAPENTIN MONOHYDRATE AND ITS PRODUCTION | WARNER LAMBERT CO | 1990-01-16 | — | — | JP | disclosed |
| JP-H0211546-A | GABAPENTIN MONOHYDRATE AND ITS PRODUCTION | WARNER LAMBERT CO | 1990-01-16 | — | — | JP | disclosed |
| US-4894476-A | ANTISCALING AGENTS | WARNER-LAMBERT COMPANY (US) | 1990-01-16 | — | — | US | disclosed |
| US-4894476-A | ANTISCALING AGENTS | WARNER-LAMBERT COMPANY (US) | 1990-01-16 | — | — | US | disclosed |
| EP-0340677-A2 | Gabapentin monohydrate and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1989-11-08 | — | — | EP | disclosed |
| EP-0340677-A2 | Gabapentin monohydrate and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1989-11-08 | — | — | EP | disclosed |
| EP-0340677-A2 | Gabapentin monohydrate and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1989-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237025-A1 | PROCESS FOR PREPARING GABAPENTIN | GABRG1, GABRD, GABRA5 | CACNA2D1 755/4885CYP1A2 348/4885ALDH1A1 479/4885 |
| US-20070287861-A1 | A Process Suitable for Industrial Scale Production of Gabapentin | SLC6A13, GABRA6, GABRB1 | CACNA2D1 244/4885CYP1A2 1948/4885ALDH1A1 599/4885 |
| US-20020198261-A1 | Liquid pharmaceutical compositions | GABRB2, GABRB1, GABRA6 | CACNA2D1 943/4885CYP1A2 1219/4885ALDH1A1 932/4885 |
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | GABRA1, GABRA6, ACMSD | CACNA2D1 261/4885CYP1A2 499/4885ALDH1A1 366/4885 |
| US-20040072904-A1 | Liquid pharmaceutical compositions | GABRB2, GABRB1, GABRA6 | CACNA2D1 943/4885CYP1A2 1219/4885ALDH1A1 932/4885 |
| US-20040054005-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | CACNA2D1 55/4885CYP1A2 1353/4885ALDH1A1 1502/4885 |
| US-20090043126-A1 | Process and Methods for the Preparation of Gabapentin and Its Intermediates | GABRB1, GABRB2, GABRB3 | CACNA2D1 416/4885CYP1A2 1293/4885ALDH1A1 547/4885 |
| US-20080318932-A1 | Sodium Channel Blocker Compositions and the Use Thereof | CACNA1B, CACNB2, CACNA1C | CACNA2D1 55/4885CYP1A2 1353/4885ALDH1A1 1502/4885 |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | CACNA2D1 55/4885CYP1A2 1353/4885ALDH1A1 1502/4885 |
| US-20080207945-A1 | Preparation of gabapentin by liquid-liquid extraction | SLC6A13, SLC6A1, SLC6A11 | CACNA2D1 126/4885CYP1A2 3760/4885ALDH1A1 4051/4885 |
| US-20070043236-A1 | Process for preparation of gabapentin | GABRG2, GABRB2, GABRA2 | CACNA2D1 68/4885CYP1A2 865/4885ALDH1A1 564/4885 |
| US-20030092933-A1 | Anhydrous crystalline forms of gabapentin | SLC6A13, GABRE, SLC6A11 | CACNA2D1 76/4885CYP1A2 2474/4885ALDH1A1 1119/4885 |
| US-20060020034-A1 | Processes for the preparation of Gabapentin | SLC6A1, GABRB2, SLC6A13 | CACNA2D1 432/4885CYP1A2 1681/4885ALDH1A1 1363/4885 |
| US-20020010371-A1 | Process for preparing a cyclic amino acid anticonvulsant compound | BCAT1, BCAT2, GABRA6 | CACNA2D1 474/4885CYP1A2 755/4885ALDH1A1 2115/4885 |
| US-20060287392-A1 | GABAPENTIN COMPOSITIONS | GABRE, GABRD, GABRA6 | CACNA2D1 343/4885CYP1A2 1226/4885ALDH1A1 910/4885 |
| US-20110306787-A1 | PROCESS FOR THE PREPARATION OF GABAPENTIN | SLC6A13, SLC6A1, SLC6A11 | CACNA2D1 35/4885CYP1A2 3113/4885ALDH1A1 1957/4885 |
| US-20060235079-A1 | Process for the preparation of gabapentin form-II | GABRE, GABRB2, GABRP | CACNA2D1 107/4885CYP1A2 953/4885ALDH1A1 2377/4885 |
| US-20040214893-A1 | tartaric acid, ethanedisulfonic acid, or maleic acid salts of gabapentin; improved aqueous solubility, and dose response properties; for treating brain disorders | SLC6A13, SLC6A11, SLC6A1 | CACNA2D1 881/4885CYP1A2 1158/4885ALDH1A1 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.